MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEW YORK, July 11, 2024 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between March 17, 2021 and May 7, 2024, both dates inclusive (the "Class Period"), of the important August 5, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. 

So what: If you purchased Marinus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Marinus class action, go to https://rosenlegal.com/submit-form/?case_id=25735 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [e-mail] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 5, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Details of the case: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial; (2) defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Marinus class action, go to https://rosenlegal.com/submit-form/?case_id=25735 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [e-mail] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40^th Floor
      New York, NY  10016
      Tel: [phone]
      Toll Free: [phone]
      Fax: [phone]
      [e-mail]
      www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mrns-investors-have-opportunity-to-lead-marinus-pharmaceuticals-inc-securities-fraud-lawsuit-filed-by-the-rosen-law-firm-302195309.html

SOURCE THE ROSEN LAW FIRM, P. A.